GlassScriptPhysician profile
Brian D Sorin
NPI 1932229911
$40,893.61
in general payments reported to CMS, 2019-2025
62 companies · $2,176 in 2025
The $2,176 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $9,441 · 2021: $8,166 · 2022: $3,053 · 2023: $2,432 · 2024: $3,014 · 2025: $2,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,622.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $9,267.39 | 2019-2025 | Ajovy, Austedo |
| Ipsen Biopharmaceuticals, INC | $8,709.61 | 2019-2025 | Dysport |
| Amgen INC. | $6,943.98 | 2019-2023 | Aimovig |
| Abbvie INC. | $3,046.66 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Lundbeck LLC | $1,697.11 | 2020-2024 | Vyepti |
| Merz Pharmaceuticals, LLC | $1,368.37 | 2021-2025 | Xeomin |
| Pfizer INC. | $824.09 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $636.95 | 2019-2025 | |
| Lilly USA, LLC | $633.29 | 2019-2024 | Emgality, Reyvow |
| Merz North America, INC. | $588.90 | 2019-2020 | |
| Revance Therapeutics, INC. | $531.08 | 2024-2025 | Daxxify |
| Allergan, INC. | $517.15 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $502.56 | 2022 | |
| Biogen, INC. | $421.32 | 2019-2022 | |
| Celgene Corporation | $419.81 | 2019-2025 | Zeposia |
Show all 61 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sorin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.